Company profile
UK company 11112130, incorporated on 14 December 2017.
Cambridge Gene Therapy Limited is a UK company with status active founded in 2017 based in East of England.
Company number 11112130
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
Cambridge Gene Therapy develops biotechnologies, designed to treat lysosomal diseases, specialising in gene therapy treatments.
This is the inception of a spin-out company (incorporated 13/12/2017) to raise the funds needed for the conduct of the planned phase 1/2 clinical trial of gene therapy in Tay-Sachs and Sandhoff diseases (GM2 gangliosidosis). At this time we have maximum allowable support from Cambridge Seed Funds and LifeArc conditional on support from one further minor partner.
Considerable interest from investors local and international. Due dilligence searches have been met and an IP strategy has been developed. A final product development plan for the lead clinical candidate is now being prepared. Novel components critical for development of gene therapy within new regulatory requirements for clinical use are available for licensing from the University generated.
